PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.co… Read more
PHAXIAM Therapeutics S.A. - Asset Resilience Ratio
PHAXIAM Therapeutics S.A. (PHXM) has an Asset Resilience Ratio of 3.74% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how PHAXIAM Therapeutics S.A.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down PHAXIAM Therapeutics S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.46 Million | 3.74% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €1.46 Million | 3.74% |
Asset Resilience Insights
- Limited Liquidity: PHAXIAM Therapeutics S.A. maintains only 3.74% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
PHAXIAM Therapeutics S.A. Industry Peers by Asset Resilience Ratio
Compare PHAXIAM Therapeutics S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for PHAXIAM Therapeutics S.A. (2016–2023)
The table below shows the annual Asset Resilience Ratio data for PHAXIAM Therapeutics S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 20.41% | €10.47 Million | €51.31 Million | -64.35pp |
| 2022-12-31 | 84.77% | €38.83 Million | €45.81 Million | +33.58pp |
| 2021-12-31 | 51.19% | €34.18 Million | €66.77 Million | -4.10pp |
| 2020-12-31 | 55.29% | €44.45 Million | €80.40 Million | -6.45pp |
| 2019-12-31 | 61.74% | €73.19 Million | €118.55 Million | -18.32pp |
| 2018-12-31 | 80.06% | €134.37 Million | €167.84 Million | -3.66pp |
| 2016-12-31 | 83.72% | €37.65 Million | €44.97 Million | -- |